LARALAB GmbH - Company Research Report

Company Overview

• Name: LARALAB GmbH

• Mission: LARALAB is dedicated to advancing the field of interventional cardiology through proprietary deep learning and cloud technology.

• Founded: 2018

• Founders: Information not explicitly found

• Key People:

• Julian Praceus, CEO & Co-Founder

• Anja Roepling, Head of Product

• Julian Bernard, COO & Co-Founder

• Alex Vasilev, Co-Founder

• Jeffrey Jedele, Head of Engineering

• Angelos Theocharis, Head of Quality & Regulatory Affairs

• Headquarters: Munich, Germany

• Number of Employees: No information is available

• Revenue: No information is available

• Known For: LARALAB GmbH is a leader in AI-driven medical imaging for interventional cardiology, especially known for innovations in transcatheter therapies such as Mitral, Tricuspid, and Aortic Valve procedures.

Products

1. LARALAB Platform

• Description: A suite of deep learning-powered tools designed for heart valve interventions.

• Key Features:

• CE-marked imaging and data analytics platform that aids in clinical decision-making.

• Supports Mitral and Tricuspid interventions.

• Offers comprehensive interventional planning for cardiac CT scans throughout the entire cardiac cycle.

2. Gen2 Platform

• Description: An advanced platform that sets a new benchmark in web-based medical imaging, specifically for mitral and tricuspid valve interventions.

• Key Features:

• Capable of processing large cardiac CT scans.

• Fully supports comprehensive interventional planning with automated AI analysis.

• Approved as CE (MDR) class IIb software as a medical product.

3. REC - Rapid Eligibility Check

• Description: A new product providing rapid, AI-driven assessments of patient eligibility for various heart procedures.

• Key Features:

• Offers quick AI-driven patient eligibility assessments.

• Color-coded system indicating suitability of treatment options.

• Capable of identifying anatomical eligibility for treatments like TAVR, TMVR, and TTVR.

• Validated with collaboration from renowned cardiologists and heart surgeons.

Recent Developments

• May 2024:

• LARALAB launched the groundbreaking product 'REC - Rapid Eligibility Check', enhancing patient screening and therapy selection through AI-driven assessments.

• April 2024:

• Launch of the 'Gen2 Platform', a major update in their platform, emphasizing innovations in web-based medical imaging technology.

• October 2023:

• Successfully closed a 5.7M € Series A2 financing round to drive platform innovations further.

• Collaboration with heart centers and device companies to enhance platform utilities.

In conclusion, LARALAB GmbH is at the forefront of utilizing AI in interventional cardiology, offering cutting-edge solutions for heart valve interventions through their innovative platforms and recent product launches. The company's recent developments, particularly in enhancing patient eligibility assessment and complex imaging technology, align with their mission to revolutionize interventional cardiology globally.